Screening for cytotoxic compounds in poor-prognostic chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Therapeutic options for chronic lymphocytic leukemia (CLL) with poor-prognostic genomic aberrations are limited.
• High-risk CLL is characterized by specific genetic alterations like 11q or 17p deletions.
• There is a need for novel therapeutic strategies targeting these aggressive forms of CLL.

Purpose of the Study:

• To identify compounds with anti-leukemia activity in high-risk CLL using the Spectrum Collection library.
• To screen for substances exhibiting cytotoxic effects on poor-prognostic CLL cells.
• To evaluate the efficacy of identified compounds in primary CLL cell cultures.

Main Methods:

• Utilized the Spectrum Collection library for compound screening.
• Assessed cytotoxic activity in vitro using fluorometric microculture cytotoxicity assays.
• Tested compounds on primary cell samples from both poor-prognostic (11q-/17p-) and favorable-prognostic (13q-) CLL patients.

Main Results:

• Out of 2,000 compounds, 65 showed similar cytotoxic effects in both prognostic groups.
• Fifteen compounds proceeded to dose-response experiments, with 12 maintaining similar cytotoxicity across subgroups.
• 5-azacytidine induced apoptosis in CLL cells with 11q or 17p deletion, and orlistat reduced lipoprotein lipase expression.

Conclusions:

• Screening compounds using primary cultures from high-risk CLL patients is a feasible approach.
• 5-azacytidine and orlistat demonstrate cytotoxicity in poor-risk CLL, offering potential therapeutic avenues.
• These findings highlight the potential of novel compounds for treating aggressive CLL.